CLINICAL TRIAL: THALIDOMIDE IN THE TREATMENT OF WOMEN WITH CHRONIC PELVIC PAIN/E

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项沙利度胺治疗与子宫内膜异位症相关的顽固性慢性盆腔疼痛的开放标签试验。参与者是那些不能耐受或未能接受所有可用常规治疗的育龄妇女，子宫切除术是唯一的替代治疗方式。我们将招募17名患有顽固性疼痛的女性。在注册之前，我们将评估基线生活质量和疼痛水平。除了连续的临床评估(每2-4周)外，我们还将监测在积极药物治疗期间肿瘤坏死因子α和白介素2水平的变化。在三个月的治疗结束后，治疗将终止。受试者将在6个月后重新评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open label trial of Thalidomide for treatment of intractable chronic pelvic pain associated with endometriosis. Participant sare reproductive age women who have been intolerant or have failed all available conventional medical therapies, with hysterectomy as the only alternative treatment modality. We will enroll 17 women with intractable pain. Prior to enrollment, we will assess baseline quality of life and pain level. In addition to serial clincial evaluation (every 2-4 weeks), we will monitor any changes in TNF alpha and interleukin level during the active drug treatment. At the end of the three month therapy, the treatment will be terminated. Subjects will be reassessed at 6 months.